Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4526188 | PMC |
| http://dx.doi.org/10.1080/01635581.2010.516476 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Inhibition of Renal Cell Carcinoma Growth by 1,3-thiazin-6-one Through Targeting the Inflammatory Reaction.
Dokl Biochem Biophys
January 2025
Nephrology Department, Liangping Hospital, Liangping District People's Hospital of Chongqing, 405299, Chongqing, China.
The current study examined the underlying mechanism and the effect of 1,3-thiazin-6-one on the growth of renal cancer. The findings showed that 1,3-thiazin-6-one treatment inhibited the growth of xenograft tumors in a dose-dependent manner in mice model of renal cancer. Furthermore, when 1,3-thiazin-6-one was administered in a dose-dependent manner to mice with renal cancer, the expression of the proteins p-PI3K and p-Akt significantly decreased.
View Article and Find Full Text PDFEfficacy of Poloxamer 188 in Carboplatin-Induced Aplastic Anemia Model in CBA Mice.
Dokl Biol Sci
January 2025
Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry Branch, Russian Academy of Sciences, Pushchino, Russia.
Poloxamer 188 (P188) was tested for effect on medullary hematopoiesis in aplastic anemia. P188 was administered to CBA mice with developing anemia via oral gavage at doses of 10, 100, and 500 mg/kg. A dose-dependent effect was observed, including an increase in erythrocyte count, hemoglobin, and reticulocyte count.
View Article and Find Full Text PDFAcute effects of psilocybin on attention and executive functioning in healthy volunteers: a systematic review and multilevel meta-analysis.
Psychopharmacology (Berl)
January 2025
Department of Clinical and Developmental Neuropsychology, University of Groningen, Groningen, the Netherlands.
Rationale: Psilocybin shows promise for treating neuropsychiatric disorders. However, insight into its acute effects on cognition is lacking. Given the significant role of executive functions in daily life and treatment efficacy, it is crucial to evaluate how psilocybin influences these cognitive domains.
View Article and Find Full Text PDFA complete sojourn on nanotechnological advancements and nanocarrier applications in psoriasis management.
Naunyn Schmiedebergs Arch Pharmacol
January 2025
Department of Pharmaceutics, ISF College of Pharmacy, GT Road, Moga, 142001, Punjab, India.
Psoriasis, a chronic autoimmune and non-communicable skin disease, affects 2-3% of the global population, creating a significant financial burden on healthcare systems worldwide. Treatment approaches are categorized based on disease severity, with first-line therapy focusing on topical treatments and second-line therapy encompassing phototherapy, systemic therapy, and biological therapy. Transdermal drug delivery methods present a promising alternative by enhancing drug absorption through the skin, potentially improving therapeutic outcomes while minimizing systemic adverse effects.
View Article and Find Full Text PDFIntratumoral or Subcutaneous MK-2118, a Non-Cyclic Dinucleotide STING Agonist, With or Without Pembrolizumab for Advanced or Metastatic Solid Tumors or Lymphomas.
Clin Cancer Res
January 2025
UC San Diego Health System, La Jolla, United States.
Background: We evaluated the non-cyclic dinucleotide stimulator of interferon genes agonist MK-2118 ± pembrolizumab in patients with advanced solid tumors or lymphomas.
Methods: This first-in-human study (NCT03249792) enrolled patients with refractory, advanced solid tumors or lymphomas. Patients received intratumoral (IT) MK-2118 100-20,000 µg (arm 1), IT MK-2118 900-15,000 µg plus intravenous (IV) pembrolizumab 200 mg every 3 weeks (Q3W; arm 2), or subcutaneous (SC) MK-2118 5000-150,000 µg plus IV pembrolizumab 200 mg Q3W (arm 4); arm 3 (visceral injection of MK-2118) was not pursued.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!